v3.26.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Feb. 10, 2026
Feb. 09, 2026
Nov. 10, 2025
Oct. 07, 2024
Mar. 31, 2026
Dec. 31, 2025
Feb. 08, 2026
Subsidiary Sale Of Stock [Line Items]              
Common stock, authorized   500,000,000     500,000,000 300,000,000 300,000,000
Preferred stock, shares authorized         10,000,000    
Common stock, outstanding         60,303,212 1,597,321  
Common stock, dividends per share declared         $ 0 $ 0  
Mezzanine equity, Preferred stock, authorized         10,000,000 10,000,000  
Issuance of common stock; net of issuance costs         $ 295,497,000    
Common stock, voting rights         Holders of Common Stock are entitled to one vote for each share of Common Stock held of record for the election of directors and on all matters submitted to a vote of stockholders.    
Preferred stock, voting rights         Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of Common Stock.    
Paramora Warrant Obligation              
Subsidiary Sale Of Stock [Line Items]              
Warrants to purchase of common stock     628,302        
Exercise price per warrant     $ 23.01        
Number of warrants exercised         0    
Underwriting Agreement              
Subsidiary Sale Of Stock [Line Items]              
Offering costs $ 20,800,000            
Sale of stock, number of shares issued in transaction 16,644,737            
Sale of stock, price per share $ 19            
Net proceeds from the underwritten offering $ 295,500,000            
Damora Therapeutics, Inc. | Underwriting Agreement              
Subsidiary Sale Of Stock [Line Items]              
Offering costs $ 20,800,000            
Sale of stock, number of shares issued in transaction 16,644,737            
Sale of stock, price per share $ 19            
Net proceeds from the underwritten offering $ 295,500,000            
Series A Non Voting Convertible Preferred Stock              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, shares authorized         200    
Preferred stock, par value         $ 0.00001    
Preferred stock, issued         159    
Preferred stock, shares outstanding         159    
Preferred stock, voting rights         The Series A Preferred Stock has no voting rights, except as required by law or to protect the rights of the holders of Series A Preferred Stock. No liquidation preference applies. Dividends, if declared on Common Stock, are payable to holders of Series A Preferred Stock on an as-if-converted-to-common-stock basis in the same form.    
Number of preferred stock converted into common stock       1,000      
Series A Non Voting Convertible Preferred Stock | Minimum              
Subsidiary Sale Of Stock [Line Items]              
Preferred Stock, issued in lieu of common stock to extent necessary to comply with percentage of limitation under Nasdaq listing rules       0.00%      
Series A Non Voting Convertible Preferred Stock | Maximum              
Subsidiary Sale Of Stock [Line Items]              
Preferred Stock, issued in lieu of common stock to extent necessary to comply with percentage of limitation under Nasdaq listing rules       19.99%      
Series B Non-Voting Convertible Preferred Stock              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, shares authorized     16,366   16,366 16,366  
Preferred stock, par value         $ 0.00001 $ 0.00001  
Preferred stock, issued         16,366 16,366  
Preferred stock, shares outstanding         16,366 16,366  
Preferred stock, voting rights         The Series B Preferred Stock does not have general voting rights; however, for so long as at least 30% of the originally issued Series B Preferred Stock remains outstanding, the Company may not, without the affirmative vote of a majority of the then-outstanding Series B shares: (i) consummate a Fundamental Transaction (as defined) or a merger or consolidation resulting in a change of control; (ii) increase the size of the board of directors; (iii) adopt, amend, or repeal certain corporate authority policies unless approved unanimously by the board of directors; or (iv) replace the Company’s registered independent public accounting firm, independent compensation consultant, or corporate counsel. The Series B Preferred Stock has no liquidation preference. Dividends, if declared on Common Stock, are payable to holders of Series B Preferred Stock on an as-if-converted basis.    
Number of preferred stock converted into common stock     1,000        
Conversion of stock, shares issued     16,366,000        
Series B Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, par value     $ 0.00001        
Preferred stock, issued     16,366        
Series C Non-Voting Convertible Preferred Stock              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, shares authorized         43,882 43,882  
Preferred stock, par value         $ 0.00001 $ 0.00001  
Preferred stock, issued     43,882   1,877 43,882  
Preferred stock, shares outstanding   1,877     1,877 43,882  
Preferred stock, voting rights         The Series C Preferred Stock does not have general voting rights, except as required by law or to protect the rights of the Series C Preferred Stock. No liquidation preference applies. Dividends, if declared on Common Stock, are payable to holders of Series C Preferred Stock on an as-if-converted basis.    
Number of preferred stock converted into common stock   42,005 1,000        
Conversion of stock, shares issued   42,005,000 43,882,000        
Stock issued during period, shares, acquisitions     4,241        
Series C Non-Voting Convertible Preferred Stock | Private Investment in Public Equity (PIPE)              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, issued     39,641        
Series C Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.              
Subsidiary Sale Of Stock [Line Items]              
Preferred stock, par value     $ 0.00001        
Preferred stock, issued     4,241        
Private Placement | Series C Non-Voting Convertible Preferred Stock | Private Investment in Public Equity (PIPE)              
Subsidiary Sale Of Stock [Line Items]              
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)     39,641        
Stock issued during period, price per shares     $ 7,186.9        
Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs     $ 267,000,000        
Offering costs     $ 18,100,000        
Private Placement | Series C Non-Voting Convertible Preferred Stock | Damora Therapeutics, Inc.              
Subsidiary Sale Of Stock [Line Items]              
Issuance of common stock in connection with offering, net of issuance costs of $20,753 (in shares)     39,641        
Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs     $ 285,000,000        
Number of preferred stock converted into common stock     1,000        
ATM Offering Program              
Subsidiary Sale Of Stock [Line Items]              
Sale of stock, number of shares issued in transaction         0    
Remaining capacity under ATM offering program         $ 150,000,000    
ATM Offering Program | Maximum              
Subsidiary Sale Of Stock [Line Items]              
Issuance of common stock; net of issuance costs $ 150,000,000            
Over-Allotment Option | Underwriting Agreement              
Subsidiary Sale Of Stock [Line Items]              
Sale of stock, number of shares issued in transaction 2,171,052            
Over-Allotment Option | Damora Therapeutics, Inc. | Underwriting Agreement              
Subsidiary Sale Of Stock [Line Items]              
Sale of stock, number of shares issued in transaction 2,171,052